Strategic Acquisition

Anupam Rasayan Announces Open Offer for 26% Stake in Bliss GVS Pharma at ₹299 per Share

NSE

BLISSGVS

BSE

506197

Anupam Rasayan India Limited announced an open offer to acquire up to 26% stake in Bliss GVS Pharma Limited at ₹299 per share following the execution of a share purchase agreement to acquire controlling stake from existing promoters and select shareholders. The transaction could increase Anupam Rasayan’s ownership in Bliss GVS Pharma to nearly 69.5% assuming full open offer acceptance.

PRICE-SENSITIVE TRIGGER

Event: Open Offer and Control Acquisition in Bliss GVS Pharma

Type: Strategic Acquisition

Impact: Positive

Immediate Effect: The transaction enables Anupam Rasayan to acquire controlling stake in Bliss GVS Pharma and enter the pharmaceutical formulations and healthcare products segment through a strategic acquisition.

Key Metrics:

Open Offer Details:

Open Offer Size:
- 2,77,26,848 equity shares
Open Offer Stake:
- 26.00% of expanded voting capital
Open Offer Price:
- ₹299 per share
Maximum Open Offer Consideration:
- ₹829.03 crore
Mode of Payment:
- Cash

Share Purchase Agreement (SPA):

Shares Under SPA:
- 4,58,03,024 shares
Stake Under SPA:
- 43.30% of existing equity capital
- 42.95% of expanded voting capital
SPA Transaction Value:
- ₹1,369.51 crore

Potential Ownership Post Transaction:

Ownership assuming full open offer acceptance:
- 69.51% equity stake
- 68.95% expanded voting capital
Ownership assuming no open offer acceptance:
- 43.30% equity stake

Additional Call Option:

Additional Optional Acquisition:
- Up to 51,81,571 shares
Additional Stake:
- 4.90% of equity capital

Highlight:

Anupam Rasayan is acquiring control of Bliss GVS Pharma through a ₹1,369 crore SPA alongside a ₹829 crore mandatory open offer at ₹299 per share.

What Happened ?

Anupam Rasayan India Limited entered into a Share Purchase Agreement dated May 23, 2026 with existing promoter and non-promoter shareholders of Bliss GVS Pharma Limited to acquire 43.30% stake in the company.

Pursuant to SEBI Takeover Regulations, the company announced a mandatory open offer to public shareholders for acquisition of an additional 26% stake at ₹299 per share in cash.

The acquisition is expected to result in:

Change in control of Bliss GVS Pharma
Reclassification of existing promoters into public category
Appointment of nominee directors by Anupam Rasayan
Strategic expansion into pharmaceutical and healthcare product segments

The transaction remains subject to:

Regulatory approvals
Satisfaction or waiver of SPA conditions precedent
Completion of open offer process

Key Details

Transaction Structure and Strategic Implications:

The open offer is being made under:
- Regulation 3(1)
- Regulation 4 of SEBI SAST Regulations
SBI Capital Markets Limited has been appointed as Manager to the Offer.
Existing sellers include:
- Shruti Vishal Rao
- Vibha Gagan Sharma
- Narsimha Shibroor Kamath
- Gautam Rasiklal Ashra
- Arjun Gautam Ashra
- Gulbarga Trading and Investment Private Limited
The transaction may be executed in one or multiple tranches under the SPA.
Anupam Rasayan also holds a call option to acquire an additional 4.90% stake from select sellers at a later stage.
Bliss GVS Pharma operates in the pharmaceutical sector and is listed on:
- NSE
- BSE
- MSE permitted trade platform
The acquirer currently holds:
- Nil pre-transaction stake in Bliss GVS Pharma
Post transaction:
- Anupam Rasayan will become promoter of Bliss GVS Pharma
- Existing promoters will exit management control
The open offer is:
- Not a competing offer
- Not conditional upon minimum acceptance
- Not intended for delisting

Strategic Relevance:

The acquisition provides Anupam Rasayan diversification beyond specialty chemicals into pharmaceuticals.
Control acquisition may create opportunities for:
- API integration
- Pharma manufacturing scale-up
- Cross-segment chemical-pharma synergies
Bliss GVS Pharma’s healthcare platform can support downstream integration opportunities for Anupam Rasayan.

Risk Analysis

Summary:

The acquisition involves large capital deployment and execution-related integration risks, while regulatory approvals and public shareholding compliance remain important monitoring factors.

Key Risks:

Transaction closure depends on:
- Regulatory clearances
- Completion of SPA conditions precedent
Integration risks include:
- Management transition
- Operational alignment
- Strategic execution
Public shareholding norms under SEBI regulations must be maintained post acquisition.
Open offer participation levels may alter final ownership structure.
Pharma sector expansion introduces:
- Regulatory compliance complexity
- Product liability risks
- Sector-specific operational challenges
Future acquisition of optional stake may involve additional capital allocation.

Worst Case Scenario:

Failure to complete transaction conditions or weaker-than-expected integration outcomes could reduce strategic benefits and impact expected diversification gains.

Risk Level: Medium

Company Commentary

Anupam Rasayan stated the acquisition is being undertaken in compliance with SEBI Takeover Regulations.
The company confirmed it has:
- Adequate financial resources
- Firm financing arrangements
- Intent to comply with all SAST obligations
The acquirer clarified:
- No person is currently acting in concert for the open offer
- There is no intention to delist Bliss GVS Pharma
The company indicated existing promoters of Bliss GVS Pharma will cease to control the target company after transaction completion.

Official Exchange Filing: Bliss GVS Pharma Limited